Celgene Stock Earnings: Key Takeaways

Celgene reported solid revenue and earnings for the second quarter, which may suggest investors are wrong to sell shares.

Todd Campbell
Todd Campbell
Jul 24, 2014 at 5:03PM
Health Care

Celgene (NASDAQ:CELG) is one of biotechnology's brightest shining stars. The company markets a slate of therapies, including its mega blockbuster multiple myeloma drug Revlimid, its fast-growing cancer drug Abraxane, and its newly launched autoimmune drug, Otezla.

Despite Celgene's growing product lineup, shares are trading lower following the company's second quarter earnings report. As a result, investors are right to wonder if Celgene's winning streak is coming to an end.

Source: Celgene through June 11, 2014

In the following slideshow, you'll learn which of Celgene's drugs grew fastest and gain insight into whether shares are worth buying.